Objective: Depression and hostility are significant risk factors for mortality and morbidity after myocardial infarction (MI). Much research is still needed to identify effective ways to reduce emotional distress in patients with cardiovascular disease. This double-blind, placebo-controlled study investigated the efficacy and safety of the antidepressant fluoxetine in patients with depression after their first MI. Methods: Fifty-four patients with major depression after MI were randomly assigned to receive a flexible-dose regimen of fluoxetine or placebo for the first 9 weeks of a double-blind, placebo-controlled trial. Patients without serious adverse effects who wished to continue participating in the study were given fluoxetine or placebo for an additional 16 weeks. To evaluate the efficacy of fluoxetine, the 17-item Hamilton Depression Rating Scale (HAMD-17) and the Hostility Scale of the 90-item Symptom Check List (SCL-90) were used as primary measures of outcome. To evaluate the safety of fluoxetine, cardiac function was measured before and after treatment with echocardiography and electrocardiography. Results: The a priori difference in antidepressive efficacy (4-point difference in HAMD-17 scores between the fluoxetine and placebo groups) was not met. However, the response rate among patients receiving fluoxetine was significantly greater than that among patients receiving placebo at week 25 (48 vs. 26%, p ϭ .05). Among patients with mild depression (HAMD-17 score Յ21), HAMD-17 scores were significantly different (p Ͻ .05) between the fluoxetine and placebo groups at weeks 9 (by 5.4 points) and 25 (by 5.8 points). Also, hostility scores at week 25 were significantly reduced among patients receiving fluoxetine (p ϭ .02). Analysis of electrocardiographic and echocardiographic parameters revealed no decrease in cardiac function as a result of treatment with fluoxetine. Conclusions: Although the overall difference between the fluoxetine and placebo groups was not significant, there was a trend favoring fluoxetine in this relatively small sample. The response rate in the group receiving fluoxetine was comparable with that observed in other studies of patients with cardiovascular disease. In addition, fluoxetine seemed to be particularly effective in patients with mild depression and was associated with a statistically significant reduction in hostility. The results of this study suggest that fluoxetine can be safely used to treat patients with post-MI depression beginning 3 months after the event. Key words: fluoxetine, major depression, myocardial infarction.
INTRODUCTION
Affective dysregulations are frequent sequelae in patients who have had an MI and increase cardiac morbidity and mortality during the first year after MI (1) (2) (3) . Of these affective dysregulations, depression and hostility are well documented and operationalized (1, (3) (4) (5) . The poorer cardiac prognosis in MI patients with affective dysregulation has heightened interest in the treatment of depression after MI and the effect of treatment on subsequent cardiac morbidity and mortality. However, antidepressants may have intrinsic adverse effects on cardiac functioning, although SSRIs have been reported to be safer than tricyclics (6) .
Data on the efficacy of SSRIs in patients with post-MI depression are limited. In elderly depressed patients with cardiovascular disease, both paroxetine and nortriptyline have been shown to reduce depression (7) . Fluoxetine was found to be less effective than nortriptyline in older, severely depressed patients with heart disease (8) . Data on the treatment of hostility are even more scarce. Fluoxetine has been found to reduce hostility in patients with personality disorder (9) , healthy volunteers (10) , and depressed patients (11) . No data on its effect on increased aggression in depressed post-MI patients are available.
Tricyclics are reported to increase heart rate, induce orthostatic hypotension, slow intraventricular cardiac conduction, and suppress ventricular premature depolarizations in depressed patients with or without heart disease (12) (13) (14) (15) . Although SSRIs are thought to be less cardiotoxic than tricyclics, available data on the safety of SSRIs in patients with ischemic heart disease or MI are limited, and these agents have not been evaluated in a double-blind, placebo-controlled trial (Table 1) . SSRIs have been found to have no cardiotoxic effects in healthy volunteers or elderly patients (16 -18) . Studies of the adverse cardiovascular effects of SSRIs in patients with somatic disease have been mainly restricted to evaluation of patients with ischemic heart disease. In an open-treatment trial of elderly patients with heart disease, fluoxetine was found to decrease heart rate and increase supine systolic pressure and ejection fraction (19) . In a comparative study with nortriptyline in depressed patients with ischemic heart disease, no adverse cardiovascular effects of paroxetine were reported (7). Fluoxetine and fluvoxamine were not found to have a negative effect on cardiac functioning (measured by echocardiography) of middle-aged and elderly depressed patients (20) .
Only one open study focusing on the adverse cardiovascular effects of sertraline in patients with post-MI depression has been published (21) . In this study, sertraline did not have negative effects on the myocardium in the 26 patients studied (21) . This is the first study to investigate the antidepressant efficacy, antihostility efficacy, and cardiac safety of fluoxetine in patients with post-MI depression using a double-blind, placebo-controlled design. We hypothesized that fluoxetine would be superior to placebo in reducing depression and hostility and would have no significant adverse cardiovascular effects.
METHODS

Subjects
The study was conducted at Maastricht University Hospital and an affiliated hospital. Patients with a first MI, which was diagnosed by a cardiologist, were included. Inclusion criteria were 1) age of 18 to 75 years, 2) a clinical picture typical of MI, 3) electrocardiographic changes specific for MI, and 4) a maximum plasma concentration of ASAT of twice the upper normal range (80 U/liter) (22) . Patients were screened for depression and hostility 1, 3, 6, and 12 months after their MI using the validated Dutch version of the SCL-90 (23).
Patients scoring above the cutoff on the SCL-90 Depression Scale (Ն23 for men and Ն28 for women) (24) at screening were invited for an interview by a psychiatrist or trained physician to determine whether they met DSM-III-R criteria for major depression. During this interview, the severity of depression was measured using the HAMD-17 (25) . Patients fulfilling DSM-III-R criteria for a major depressive episode, diagnosed by use of a DSM-III-R checklist based on sections 6, 7, 8, and 21 of the Schedules for Clinical Assessment in Neuropsychiatry (26) , and having a HAMD-17 score Ͼ17, could be enrolled in the trial from month 3 to month 12 after MI. During the first 3 months after MI, it can be difficult to distinguish depressive symptoms as either 1) components of a major depressive episode, 2) sequelae of a sudden catastrophic cardiac event, or 3) signs of a temporary decrease in cardiac functioning. In addition, some patients participated in a routine cardiological rehabilitation program, consisting of physical therapy and psychological education, that lasted up to 3 months after the MI. Our treatment design did not permit any concurrent psychosocial or therapeutic intervention.
Exclusion criteria were psychotic symptomatology, a second psychiatric diagnosis, history of mania, current pregnancy or lactation, life-threatening noncardiac physical illness, concurrent use of psychotropic drugs (except oxazepam up to 50 mg/d), hypersensitivity to fluoxetine, and liver or severe kidney dysfunction (creatinine clearance Ͻ10 ml/min). We included all post-MI patients except those with a right ventricular filling pressure Ͼ30 mm Hg and a low systolic volume or an ATVI Ͻ20 cm. High filling pressure and low output may result in listlessness and a lack of energy and drive, a condition mimicking depression (27) . Impairment of LVEF was not used as an exclusion criterion. The study was approved by the ethics committees at the two sites. The study was completely described to the subjects, who then provided written informed consent.
Subjects were recruited from May 1994 to December 1997. The number of eligible patients was 556, of whom 357 (64%) agreed to participate and 199 (36%) declined to participate. Of these 357 subjects, 4 died between 1 and 3 months after MI, and 68 met DSM-III-R criteria for major depression (Figure 1 ). Of the 68 depressed patients, 12 dropped out at a later stage, and 2 were excluded because of an ATVI Ͻ20 cm and a right ventricular filling pressure Ͼ30 mm Hg. Nonparticipants did not differ from participants in age, gender, or maximum ASAT. Hence, 54 patients were included in the study, of whom 31 were diagnosed with a major Paroxetine Depressed patients with ischemic heart disease (N ϭ 41) Heart rate 2 Nortriptyline Heart rate 1, HRV 2 Strik et al. (20) , 1998
Fluoxetine Middle-aged and elderly depressed patients (N ϭ 20) Ejection fraction 1 in patients with heart disease Fluvoxamine HRV ϭ heart rate variability; 1 ϭ increase; 2 ϭ decrease. depressive episode at 3 months after MI; 17, at 6 months; and 6, at 12 months. These 54 patients were randomly assigned to receive fluoxetine (N ϭ 27) or placebo (N ϭ 27).
Intervention
Fluoxetine was studied using a randomized, placebo-controlled, double-blind design. The antidepressant was prescribed for a maximum of 25 weeks; the acute treatment period lasted 9 weeks, and the continuation period lasted another 16 weeks. Patients were randomly assigned to receive either fluoxetine 20 mg/d or placebo. The dose of fluoxetine could be increased to 40 mg/d in week 3 and to 60 mg/d in week 6 depending on the clinical response (dose was increased if there was a Ͻ50% decrease in the HAMD-17 score). Spontaneously reported adverse effects were categorized as gastrointestinal complaints, chest pain, agitation, and other complaints. Patients who were rehospitalized were dropped from the study and offered additional antidepressant treatment. At week 9, patients who wished to continue participating in the trial were allowed to do so and were given the same dose of fluoxetine or placebo for another 16 weeks regardless of their response (even if there was a Ͻ50% reduction in HAMD-17 score).
Data Collection
Depression, hostility, adverse effects and events, and concurrent use of medications were assessed at baseline and weeks 1, 3, 6, and 9; thereafter these parameters were measured monthly. Serious adverse events were defined as death, rehospitalization due to cardiac events, and noncardiac life-threatening disease. Blood pressure, height, and weight were measured at baseline and at weeks 6, 9, and 25 (except weight). Blood and urine samples were collected at the same time points for hematological testing, clinical chemistry screening, and measurement of plasma concentrations of fluoxetine and norfluoxetine. Electrocardiography and echocardiography were performed at baseline and weeks 6 and 25.
Response and remission were assessed for patients who had at least one assessment after initiation of treatment. Response was defined as a 50% or greater reduction in the HAMD-17 score. Remission was defined as a HAMD-17 end-point score Ͻ7. Changes in scores on the SCL-90 Hostility Scale were used to assess the efficacy of fluoxetine as a treatment for hostility. According to Dutch SCL-90 standards, a score of 9 to 11 indicates a high level of hostility; 8 to 9, moderate; and Ͻ8, low (23) . Because there is no clear consensus on hostility response or remission, no cutoff was operationalized.
The present study focused not only on changes in cardiac conduction and blood pressure but also on changes in cardiac output. Safety measures therefore were electrocardiographic variables, systolic and diastolic blood pressures, and echocardiographic variables. Electrocardiographic variables consisted of heart rate, PR interval, QRS interval, and QT c interval. Impaired conduction may lead to an increase in the QRS interval. Enlargement of the QT c interval has been related to arrhythmias. LVEF and ATVI were monitored by echocardiography. ATVI was used as an indirect measure of stroke volume (28, 29) , which is related to cardiac output. ATVI multiplied by the aortic valve area (Doppler method) was used to calculate stroke volume. Parameters to assess diastolic function or filling pressures were defined as early or passive/active or late mitral inflow (E/A ratio) (30) .
Statistical Analyses
The required sample size was estimated using the method of Knapp and Miller (31) . If previous outcome data are unavailable for depressed post-MI patients, these guidelines suggest approximating the standard deviation by dividing the range of values for the response variable (HAMD-17 score) by 6 (31). A mean of 26 HAMD points was taken as the range (32, 33 ). An effect size of a 4-point difference in HAMD-17 scores between the fluoxetine and placebo groups and a statistically significant difference in response rate between the fluoxetine and placebo groups was thus expected a priori (34) . If the level of significance ␣ is set at .05, the power ␤ is set at 0.95, and the HAMD-17 hypothesis is tested using a one-tailed test, the required sample size is 54 (27 per group).
Statistical analyses were performed using STATA 5.0 (35) and SPSS for Windows 6.0 software (36) . To analyze the efficacy data, t tests were used, given the absence of outliers and presence of normality of data tested with skewness/kurtosis test (37) . Efficacy outcome was analyzed on an intention-to-treat basis: All 54 patients were analyzed as they were randomized. For patients not completing the 9 or 25 weeks of treatment, the "last observation carried forward" technique (38) was used. Increases in HAMD-17 or SCL-90 hostility scores during fluoxetine treatment were unlikely because fluoxetine has established antidepressive (32, 33) and antihostility properties (9) . Therefore, tests of the primary efficacy variables (scores on the HAMD-17 and SCL-90 Hostility Scale) were one tailed. All other tests were two tailed.
To determine the safety of fluoxetine therapy, regression analyses were applied using cardiologic safety variables as dependent variables and treatment condition and fluoxetine plasma concentration as independent variables. Regression analyses were performed as described by Kleinbaum et al. (39) . When there were large Cook distances (Ͼ3 SDs), a second regression model was assessed without influential cases. Patients were included in these analyses only if assessment data from baseline and week 6 or baseline and week 25 were available. Fig. 1 . Flow chart of depressed patients eligible for the study.
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RESULTS
There were no statistically significant differences between the fluoxetine and placebo groups in age, gender, severity of depression, severity of hostility at baseline (using HAMD-17 and SCL-90 hostility scores), or severity of MI (maximum ASAT) ( Table 2) .
During the acute treatment phase of the study (up to week 9), two patients from the fluoxetine group and five from the placebo group dropped out; during the continuation phase (weeks 10 to 25), three patients from the fluoxetine group and four from the placebo group dropped out because of a lack of effect, loss to follow-up, or medical reasons (Figure 1 ). All patients taking fluoxetine had a plasma level of fluoxetine Ͼ4 g/liter on repeated measurements. Mean plasma levels of fluoxetine and norfluoxetine were 74.8 (SD ϭ 55.1) and 58.6 g/liter (SD ϭ 29.7), respectively, at week 3; 131.3 (SD ϭ 92.2) and 104.2 g/liter (SD ϭ 57.0), respectively, at week 6; 175.8 (SD ϭ 138.0) and 129.5 g/liter (SD ϭ 84.8) at week 9; and 154.3 (SD ϭ 144.7) and 139.9 g/liter (SD ϭ 115.5) at week 25, respectively. The mean fluoxetine dose was 47.3 mg/d (SD ϭ 19.1).
Concurrent Medications
Medications used concurrently included aspirin (N ϭ 42, 77.8%), lipophilic ␤-blockers (N ϭ 33, 61.1%), benzodiazepines (N ϭ 28, 51.9%), isosorbide nitrate (N ϭ 23, 42.6%), cholesterol-lowering medication (N ϭ 22, 40.7%), angiotensin-converting enzyme inhibitors (N ϭ 16, 29.6%), calcium channel blockers (N ϭ 15, 27.8%), diuretics (N ϭ 13, 24.1%), anticoagulants (N ϭ 6, 11.1%), and hydrophilic ␤-blockers (N ϭ 5, 9.3%). The median number of cardiovascular drugs taken was 4.9 (range ϭ 1-9) excluding the trial medication. There were no differences in specific drugs between groups (all p values Ͼ .10). No patients were taking antidepressant or antipsychotic drugs before the study.
Adverse Effects and Events
Patients in both groups reported adverse effects, mainly chest pain, gastrointestinal complaints, and agitation (Table 3) , but there were no significant differences between groups in the number of events reported. The only serious adverse event that occurred was rehospitalization for a cardiac event (N ϭ 7) ; no patients were excluded because of cancer, drug overdose, or death during this study. The mortality rate of MI patients in general in our hospital is highest during acute hospitalization and decreases to 1 to 2% between 1 and 12 months after MI (40) . Patients were rehospitalized for one of the following reasons: unstable angina pectoris, anemia, ventricular fibrillation, decompensatio cordis, and catheterization. The number of rehospitalizations was higher in the placebo group (N ϭ 6) than in the fluoxetine group (N ϭ 1), but this difference was not statistically significant (p ϭ .13). a Values for all characteristics except gender are mean (SD). DBP ϭ diastolic blood pressure; SBP ϭ systolic blood pressure. b Differences in baseline characteristics between the fluoxetine and placebo groups were not statistically significant. 
Efficacy During the Acute Treatment Phase
The mean HAMD-17 score decreased 8.34 points (SD ϭ 5.87) in the fluoxetine group and 5.84 points (SD ϭ 5.92) in the placebo group (Figure 2, left) . The difference of 2.50 HAMD points was not statistically significant at week 9 (t ϭ 1.56, df ϭ 52, p ϭ .06). Nine patients receiving fluoxetine and 8 receiving placebo responded; remission occurred in 3 receiving fluoxetine and 1 receiving placebo. Differences were not significant (p ϭ .39 and p ϭ .15, respectively) . The mean SCL-90 hostility score decreased 2.61 points (SD ϭ 3.06) in the fluoxetine group and 1.18 points (SD ϭ 4.12) in the placebo group (Figure 3, left) . This difference of 1.44 points was not statistically significant (p ϭ .08). Use of benzodiazepine had no influence on the HAMD-17 score, hostility score, response rate, or remission rate.
Efficacy During the Entire Treatment Phase
From baseline to week 25, the total HAMD-17 scores decreased 9.65 points (SD ϭ 7.17) in subjects receiving fluoxetine and 6.92 points (SD ϭ 6.91) in subjects receiving placebo (Figure 2, right) . This difference was not statistically significant (p ϭ .08). However, at week 25 there were 13 responders in the fluoxetine group (48%) and 7 in the placebo group (26%) ( 2 ϭ 2.86, df ϭ 1, p ϭ .05). Remission occurred in 7 responders (26%) in the fluoxetine group and in 4 responders (14.8%) in the placebo group (p ϭ .6).
The SCL-90 hostility score decreased by 2.44 points (SD ϭ 4.64) in patients receiving fluoxetine and by 0.07 points (SD ϭ 2.57) in patients receiving placebo (t ϭ 2.32, df ϭ 52, p ϭ .02) (Figure 3, right) . Efficacy outcome was not related to plasma levels of fluoxetine. Benzodiazepines had no influence on efficacy outcome during the entire treatment phase.
Post hoc analysis revealed that fluoxetine was more effective in patients with mild depression (HAMD-17 score Յ21, N ϭ 32) than in those with severe depression (HAMD-17 score Ͼ21, N ϭ 22); the difference in efficacy (HAMD-17 score) was 5.4 points at week 9 (p ϭ .01) and 5.8 points at week 25 (p ϭ .04).
Adverse Cardiovascular Effects
The echocardiographic variables LVEF, ATVI, and E/A ratio and the electrocardiographic variables heart rate, PR interval, QRS interval, and QT c interval did not change during the acute treatment phase (Table 3) . Between baseline and week 25, ATVI increased by 3.8 cm in the placebo group compared with the fluoxetine group (p ϭ .02). QRS interval decreased by 6.3 ms in the fluoxetine group compared with the placebo group (p ϭ .03).
Cardiac safety variables were not related to plasma levels of fluoxetine.
DISCUSSION
This study was the first to investigate the efficacy and safety of fluoxetine using a double-blind, placebocontrolled design in patients with major depression after their first MI. Overall, the difference in antidepressive efficacy (4-point difference in HAMD-17 scores between the fluoxetine and placebo groups) defined at the beginning of the study was not met. However, there were significantly more responders among the fluoxetine group than among the placebo group at week 25. Furthermore, compared with placebo, fluoxetine was especially effective in reducing the HAMD-17 score of patients with mild depression. In addition, hostility scores were significantly lower in the fluoxetine group after treatment.
The difference of 2.5 HAMD-17 points between the 
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fluoxetine and placebo groups was lower than our a priori rigorous effect size of 4.0 points. However, if we look at response rate, the commonly used efficacy outcome, the antidepressant efficacy was comparable to that reported by Roose et al. (7) and Shapiro et al. (21) . In the intention-to-treat analysis, 33% (9 of 27) of patients receiving fluoxetine responded at week 9, and 48% (13 of 27) of these patients responded at week 25.
Of patients included in the end-point analyses, 36% responded at week 9 and 59% responded at week 25.
In the placebo group, the response rate was 30% at week 9 and 26% and week 25 in the intention-to-treat analysis and 36 and 39%, respectively, in the endpoint analyses. The difference in response rate between the fluoxetine and placebo groups was statistically significant at week 25 (p ϭ .05). The response rate in the fluoxetine group in the end-point analysis (59%) is comparable with that reported by Shapiro et al. (21), who observed a response rate of 62.5% among depressed patients treated with sertraline after an acute MI. Shapiro et al. found this response rate after 16 weeks of treatment, as compared with 25 weeks in our study.
The smaller-than-expected difference in HAMD-17 scores between the fluoxetine and placebo groups in our study may be due to the relatively high response to placebo in patients with mild depression. The selflimiting course and higher placebo response may also be related to age (41) and somatic disease (41, 42) . Especially in this population, just seeing a physician in a hospital at regular intervals may be regarded as an intervention in itself, increasing the placebo response. Finally, there are studies suggesting that SSRIs are more efficacious in patients with mild depression than in those with severe depression (43) (44) (45) .
Hostility levels among patients receiving fluoxetine changed from high to low by the end of the treatment period. Because hostility reportedly increases mortality after MI, a decreased level of hostility might influence a patient's post-MI prognosis (3, 4) .
There were no significant changes in echocardiographic or electrocardiographic variables or blood pressure during the acute treatment phase. During the entire treatment period of 25 weeks, ATVI decreased in the fluoxetine group as compared with the placebo group. In this same period, QRS interval decreased by 6.3 ms in the fluoxetine group as compared with the placebo group. Adverse effects (mainly chest pain, gastrointestinal symptoms, and agitation) were reported equally in both groups. Rehospitalization for cardiac events occurred mainly in the placebo group.
QRS interval decreased during the continuation phase among patients receiving fluoxetine, but a change in the QRS complex of Ͻ10 ms in patients with a QRS complex Ͻ110 ms is not considered clinically relevant, which was the case in patients of this study. Furthermore, the difference in cardiac output or ATVI between the fluoxetine and placebo groups disappeared after correction of ATVI for both heart rate and maximum ASAT. This could be explained by the fact that ATVI is influenced by maximum ASAT or severity of MI, with a larger MI leading to a lower ATVI (29) . Thus, the decrease in ATVI in the fluoxetine group seemed not to be caused by fluoxetine but by cardiac variables.
The main limitation of our study was the sample size, which was probably not large enough to reach a 4-point or greater difference in HAMD-17 scores between the fluoxetine and placebo groups. Hence, generalizations based on these results must be made carefully.
In summary, the results suggest that fluoxetine can be safely used in patients with major depression starting 3 months after MI. Although the overall difference between treatment with fluoxetine and placebo was not statistically significant, there was a clear trend favoring fluoxetine in this relatively small sample. Fluoxetine was especially effective in patients with mild depression (HAMD-17 score Յ21), and there was a statistically significant reduction in hostility among these patients. Moreover, the rate of rehospitalization was lower among patients who received fluoxetine for post-MI depression. By affecting depression and hostility, fluoxetine may reduce the risk of increased morbidity and mortality due to affective dysregulation in post-MI patients. Follow-up studies and placebo-controlled intervention trials must be performed to verify these conclusions.
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